穴位刺激调控法治疗强迫症患者的临床观察

目的 研究穴位刺激调控法治疗强迫症的临床疗效。方法 将强迫症患者65例分为氯米帕明组33例和穴位刺激调控组32例，进行对照研究。用Yale-Brown强迫症量表（Y-BOCS）评定疗效和不良反应。结果 氯米帕明组痊愈率为24．2％（8／33例），显效率为27．3％（9／33例）。穴位刺激调控组痊愈率为37．5％（12／32例），显效率为34。4％（11／32例）。第4周末起两组间的Y—BOCS评分的差异有显著性（P〈0．05），穴位刺激调控组疗效优于氯米帕明组。氯米帕明组不良反应发生率显著高于穴位刺激调控组。结论 穴位刺激调控组疗效优于氯米帕明组、不良反应小。安全性好。

Clinical Study on Treatment of Obsessive Compulsive Neurosis by Acupoint Stimulating Control

ObjectiveTo study the clinical effect of acupoint stimulating control (ASC) in treating obsessive compulsive neurosis. MethodsThe comparative study was conducted in 65 patients with obsessive compulsive neurosis, they were divided into two groups, the 33 patients in the control group treated with chlorimipramine and the 32 in the tested group treated with ASC. The therapeutic efficacy and adverse reaction were assessed according to the standard for clinical efficacy evaluation by Yale-Brown scale for obsession (Y-BOCS)and adverse reaction scale. ResultsThe curative rate and markedly effective rate in the control group was 24.2% (8/33) and 27.3% (19/33), which in the tested group was 37.5% (12/32) and 34.4% (11/32) respectively. Significant difference was shown in comparison of Y-BOCS score between the two groups from the end of the 4th week of treatment (P<0.05), indicating the efficacy in the tested group was better than that in the control group. Moreover, the occurrence of adverse reaction was higher in the control group than that in the tested group. ConclusionASC is a treatment with good effect, less adverse reaction and favourable safety superior to the treatment by chlorimipramine.